apramycin and Gram-Negative-Bacterial-Infections

Aminoglycoside antibiotics are powerful bactericidal therapeutics that are often used in the treatment of critical Gram-negative systemic infections. The emergence and global spread of antibiotic resistance, however, has compromised the clinical utility of aminoglycosides to an extent similar to that found for all other antibiotic-drug classes. Apramycin, a drug candidate currently in clinical development, was suggested as a next-generation aminoglycoside antibiotic with minimal cross-resistance to all other standard-of-care aminoglycosides. Here, we analyzed 591,140 pathogen genomes deposited in the NCBI National Database of Antibiotic Resistant Organisms (NDARO) for annotations of apramycin-resistance genes, and compared them to the genotypic prevalence of carbapenem resistance and 16S-rRNA methyltransferase (RMTase) genes. The 3-

Topics: Acetyltransferases; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Catalytic Domain; Databases, Genetic; Drug Resistance, Bacterial; Genome, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Methyltransferases; Molecular Epidemiology; Mutagenesis, Site-Directed; Nebramycin; Standard of Care; Structure-Activity Relationship

Topics: Animals; Cross-Over Studies; Drug Interactions; Escherichia coli; Female; Gentamicins; Gram-Negative Bacterial Infections; Injections, Intramuscular; Injections, Intravenous; Male; Microbial Sensitivity Tests; Nebramycin; Poultry Diseases; Salmonella; Turkeys